A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Filgotinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 07 Jul 2017 Planned End Date changed from 1 May 2019 to 1 Aug 2019.
- 07 Jul 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Jul 2019.
- 10 Apr 2017 Status changed from not yet recruiting to recruiting.